AbbVie — full event log
Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.
← back to Data by year2025· 16 events
AbbVie has a centralized Renewable Energy fund to increase active sourcing of renewable electricity. Progress reached 83.2% by year-end 2025 (up from 29.5% in 2021 baseline), with target of 100% by 2030. AbbVie procures renewable electricity through Energy Attribute Certificates including RECs, IRECs and European Guarantees of Origin. On-site photovoltaic solar installations operate at six sites: Ballytivnan (Ireland), Barceloneta (Puerto Rico), Campoverde (Italy), Ludwigshafen (Germany), Heredia (Costa Rica), and Liège (Belgium). Campoverde solar plant expansion delivered ~900 tCO2e annual savings.
sustainability_report p.50
AbbVie established new environmental targets effective 2026: establish water management plans at all high-risk sites by 2030; reduce net water intake normalized to revenue by 10% by 2035 from 2025 base year; reduce hazardous and non-hazardous waste normalized to revenue by 10% by 2035 from 2025 base year.
sustainability_report p.49
Ten internal manufacturing locations (two of which are shared R&D facilities) and two commercial affiliate offices are currently ISO 45001 certified.
sustainability_report p.44
In 2025 AbbVie completed acquisitions and licensing of Capstan Therapeutics, Nimble Therapeutics, Gilgamesh Pharmaceuticals, Ichnos Glenmark Innovation, Gubra and ADARx Pharmaceuticals, bolstering pipeline with more than $5 billion in business development.
sustainability_report p.7
AbbVie surpassed its 2015 baseline-based 20% water withdrawal reduction target, achieving 20.1% reduction including noncontact cooling water.
sustainability_report p.48
During 2025 AbbVie developed robust calculator tools to measure emissions across applicable Scope 3 categories and created visual overviews of the data-collection process. Long-term decarbonization plan aligned with 1.5°C pre-industrial baseline is being developed.
sustainability_report p.51
Renewable electricity purchases increased from 60% globally in 2024 to over 80% in 2025, driving significant Scope 2 market-based emissions reductions.
sustainability_report p.52
Conducted geographic biodiversity risk screening of third-party manufacturing locations using WWF Biodiversity Risk Filter; identified five priority sites for further evaluation of biodiversity-related dependencies and impacts.
sustainability_report p.58
By 2035 all packaging shall be widely recoverable and recyclable; by 2035 all packaging not classified as contact sensitive to include 30% recycled content; by 2030 transportation packaging shall not exceed 40% empty space.
sustainability_report p.56
AbbVie has not purchased, and does not currently anticipate purchasing, carbon offset credits to meet its near-term science-based targets. Decarbonization relies on direct operational reductions, fleet electrification, energy efficiency, renewable electricity procurement, and supplier engagement rather than removals or offsets.
sustainability_report p.52
Centralized capital expenditure fund supports energy-efficiency and GHG-reduction projects. In 2025, $15.1 million was allocated to approximately 65 projects (solar upgrades, boilers, chillers, insulation, heat recovery, air compressors, VSDs, LED lighting, HVAC), expected to cut ~3,700 tCO2e. Achieved 8% Scope 1+2 reduction since 2021; targeting 5–7% additional reduction by 2030.
sustainability_report p.50
Project Green Wave promotes business prioritization and employee selection of electric, hybrid and biofuel vehicles. By end of 2025, AbbVie had more than 4,800 electric and hybrid vehicles globally (up from ~1,300 in 2021). Achieved 1.5% Scope 1 reduction; targeting 7–10% Scope 1 reduction by 2030.
sustainability_report p.50
Ongoing assessment of global affiliate real estate footprint and optimization of manufacturing capabilities and sites. Achieved 21.5% Scope 1+2 reduction since 2021; targeting 10–15% reduction by 2030. AbbVie is integrating resiliency, energy efficiency and decarbonization into design and construction of new facilities, including a $100 billion US R&D and capex commitment over the next decade.
sustainability_report p.50
Engagement focuses on encouraging suppliers in Purchased Goods & Services, Capital Goods, and Upstream Transportation & Distribution categories to set their own SBTi-aligned targets. By end of 2025, 51.4% of suppliers (by emissions in these categories) had set science-based GHG reduction targets, up from 15.7% in 2021 baseline; 2027 target is 79.1%.
sustainability_report p.50
AbbVie follows the Twelve Principles of Green Chemistry and uses pervaporation (membrane-based solvent reduction) and thin film evaporation at North Chicago API Pilot Plant to reduce solvent use, energy and waste. Multiple R&D sites earned My Green Lab certifications in 2025 (e.g., Pringy, France: Green Level).
sustainability_report p.55
Launched PCF Roadmap in 2025 using PAS 2090:2025 framework, with pilots in select markets and plans to expand across portfolio over three years. New SYNTHROID bottle cut plastic >23%; new MAVYRET blister cut plastic >280g/pack and paper 120g/pack; SkinMedica primary packaging 90% recyclable.
sustainability_report p.56
2022· 1 event
In 2022, AbbVie established a global three-part emissions target validated by SBTi in March 2023: reduce absolute Scope 1+2 (market-based) emissions 42% by 2030 from 2021 baseline; increase active sourcing of renewable electricity to 100% by 2030; 79.1% of suppliers by emissions to set science-based targets by 2027.
sustainability_report p.48